By continuing to use our site, you consent to the processing of cookies, user data (location information, type and version of the OS, the type and version of the browser, the type of device and the resolution of its screen, the source of where the user came from, from which site or for what advertisement, language OS and Browser, which pages are opened and to which buttons the user presses, ip-address) for the purpose of site functioning, retargeting and statistical surveys and reviews. If you do not want your data to be processed, please leave the site.

Replica Analytics Blog

  • Oct, 28 2020

    Synthetic data has the potential to help address some of the most intractable privacy and security compliance challenges related to data analytics.

  • Sep, 21 2020

    Stephen Bamford, Janssen’s Head of Clinical Data Standards & Transparency, discusses the company’s commitment to clinical trial data transparency and sharing, and the ways in which privacy enhancing technologies (PETs) are employed to help fulfill that commitment.

  • Aug, 19 2020

    Due to contemporary surveillance laws in the United States, on July 16th the European Union’s Court of Justice ruled that E.U. data was not adequately protected under the existing Privacy Shield agreement with the U.S.

  • Aug, 07 2020

    As the pace of technological innovation continues to grow, new risks to consumer and patient privacy are appearing at a rate which could be difficult for regulators to keep up with.

  • Feb, 20 2020

    The adoption of Artificial Intelligence (AI) technologies in healthcare could lead to great improvements in efficiency, patient care and medical research, accelerating the discoveries that lead to new cures. 

  • Dec, 10 2019

    In the webinar organized by Replica Analytics in November 2019 entitled "Managing the Risks from AI Algorithms," Daniel Shapiro and Khaled El Emam discussed some of the risks in developing and using AI tools, with an emphasis on healthcare applications.

  • Jul, 01 2019

    In June 2019 we generated synthetic clinical trial data for the inaugural Vivli-Microsoft Data Challenge. The goal of the competition was to propose innovative methods to facilitate the sharing of rare disease datasets, in a manner that maintains the analytic value of the data while safeguarding participant privacy. 

  • May, 10 2019

    In May 2019, the Cutter Consortium published an executive update on synthetic data that is intended to inform technology and analytics executives about what synthetic data is and when it can be applied.

  • Apr, 24 2019

    On 21st June Vivli and Microsoft will be hosting an innovation challenge (datathons) on methods and technologies to perform privacy-protective analysis on rare disease clinical trial datasets. The challenge will take place for a full day in Boston.

  • Apr, 12 2019

    As we are working through a number of data generation projects, one issue that has come up a few times is the extent to which synthetic data is constrained by original data.